Stereotactic Body Radiotherapy for Various Cancers: Recent Advances and Future

Dear Colleagues,

Stereotactic body radiotherapy (SBRT) has been established as a definitive treatment for Stage I non-small cell lung cancer (NSCLC), prostate cancer, hepatocellular carcinoma, kidney cancer, spinal metastases, and oligometastases. Considering the effectiveness of SBRT in these tumors, indication of SBRT may be expanded to include malignant tumors of other organs or cancer status. The strong points of SBRT are high radicality, minimum invasiveness, short treatment term with ultra-hypofractionation, and probably immunological enhancement.  Recently, abscopal effect of radiation has been come into the spotlight according to appearance of SBRT and immune-checkpoint inhibitors. In spite of these topics, SBRT has not been reasonably popularized. Therefore, the aim of this special issue is to explore expanding the role of SBRT for more patients including not only medically inoperable, aged, or high risk operable but toward clearly operable patients. Original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: to demonstrate the current status in various cancers or disease status, recent advances in irradiation technique, and future possibilities or problems of SBRT.

I look forward to receiving your contributions.

Dr. Hiroshi Onishi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.